

William K Oh

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/54536/william-k-oh-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

353
papers

13,682
citations

59
h-index

107
g-index

393
ext. papers

16,313
ext. citations

6.4
avg, IF

6.21
L-index

#	Paper	IF	Citations
353	Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.. <i>Oncologist</i> , 2022 ,	5.7	2
352	Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer.. <i>Breast Cancer Research and Treatment</i> , 2022 , 192, 313	4.4	
351	Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 112-112	2.2	0
350	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.. <i>European Urology</i> , 2022 ,	10.2	2
349	Reply to Carlos G. Wambier and Gerard J. Naudin. Letter to the Editor re: Karin Welb, Ebba Rosendal, Magnus Gissl, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. <i>Eur Urol</i> . In press.	10.2	
348	Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2022 , 20 Suppl 9, 1-20	0.6	
347	Clinical observations regarding the use of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.. <i>Clinical Advances in Hematology and Oncology</i> , 2022 , 20 Suppl 9, 13-16	0.6	
346	Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A.. <i>Clinical Advances in Hematology and Oncology</i> , 2022 , 20 Suppl 9, 16-17	0.6	
345	Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging?. <i>Journal of Kidney Cancer and VHL</i> , 2021 , 8, 13-19	1.4	
344	Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. <i>Clinical Cancer Research</i> , 2021 , 27, 4287-4300	12.9	9
343	Prostate cancer intensive, non-cross reactive therapy (PRINT) for CRPC: Interim analysis of efficacy endpoints.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e17027-e17027	2.2	
342	A Rapid Guidance Process for the Development of an Anticoagulation Protocol in the COVID-19 Pandemic. <i>Quality Management in Health Care</i> , 2021 , 30, 276-279	1	
341	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. <i>Oncologist</i> , 2021 , 26, e1226-e1239	5.7	3
340	Prostate Cancer Dormancy and Reactivation in Bone Marrow. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
339	Risk Factors for Emergency Room and Hospital Care Among Patients With Solid Tumors on Immune Checkpoint Inhibitor Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021 , 44, 114-120	2.7	0
338	The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 41-41	2.2	4
337	Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 743-749	6.2	2

336	Consensus report: Definition and interpretation of remission in type 2 diabetes. <i>Diabetic Medicine</i> , 2021 , e14669	3.5	2
335	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Diabetes Care</i> , 2021 ,	14.6	15
334	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	4
333	Consensus report: definition and interpretation of remission in type 2 diabetes. <i>Diabetologia</i> , 2021 , 64, 2359-2366	10.3	7
332	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 ,	6.2	3
331	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2021 , 11, 734963	5.3	0
330	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020 , 3, e2021692	10.4	19
329	Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHARTED trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 638-645	6.2	3
328	Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. <i>Blood</i> , 2020 , 136, 144-147	2.2	85
327	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
326	Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <i>Annals of Oncology</i> , 2020 , 31, 745-759	10.3	303
325	Type, timing, and risk factors associated with immune-related adverse event development in patients with advanced genitourinary cancers treated with immune checkpoint inhibitor.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 480-480	2.2	2
324	Smoking status and immunotherapy outcomes in smoking-associated cancers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15097-e15097	2.2	
323	What happens at radiographic disease progression in patients with metastatic cancer receiving immune checkpoint inhibitors? A single institution analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15157-e15157	2.2	2
322	Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15160-e15160	2.2	1
321	Predictors of successful randomized phase III studies in the treatment metastatic renal cell carcinoma: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17105-e17105	2.2	
320	F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. <i>Practical Radiation Oncology</i> , 2020 , 10, 354-362	2.8	5
319	Does androgen deprivation therapy protect against severe complications from COVID-19?. <i>Annals of Oncology</i> , 2020 , 31, 1419-1420	10.3	41

318	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020 , 1, 1041-1053	15.4	18
317	Treatment of muscle-invasive and advanced bladder cancer in 2020. <i>Ca-A Cancer Journal for Clinicians</i> , 2020 , 70, 404-423	220.7	147
316	Lacrimal sac adenocarcinoma managed with androgen deprivation. <i>American Journal of Ophthalmology Case Reports</i> , 2020 , 19, 100607	1.3	1
315	Hospitalised COVID-19 patients of the Mount Sinai Health System: a retrospective observational study using the electronic medical records. <i>BMJ Open</i> , 2020 , 10, e040441	3	23
314	-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020 , 4, 382-392	3.6	26
313	Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. <i>Molecular Cancer Research</i> , 2019 , 17, 1605-1612	6.6	11
312	Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019 , 76, 782-789	10.2	22
311	The evolving landscape of immunotherapy in advanced prostate cancer. <i>Immunotherapy</i> , 2019 , 11, 903-918	3.8	9
310	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. <i>European Urology</i> , 2019 , 76, 599-603	10.2	50
309	Renal Cancer 2019 , 43-55		
308	Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 184-184	2.2	1
307	Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018 , 78, 2065-2080	10.1	41
306	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. <i>European Urology</i> , 2018 , 73, 751-759	10.2	67
305	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018 , 73, 178-211	10.2	313
304	Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e411-e419	3.3	25
303	Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. <i>Journal of Urology</i> , 2018 , 200, 1264-1272	2.5	53
302	Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. <i>OncoTargets and Therapy</i> , 2018 , 11, 2141-2147	4.4	22
301	The role of ketoconazole in current prostate cancer care. <i>Nature Reviews Urology</i> , 2018 , 15, 643-651	5.5	23

300	Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy. <i>Brachytherapy</i> , 2018 , 17, 874-881 ^{2,4}	2.4	1
299	Prostate cancer characteristics in the World Trade Center cohort, 2002-2013. <i>European Journal of Cancer Prevention</i> , 2018 , 27, 347-354	2	11
298	Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers. <i>Journal of Oncology Practice</i> , 2018 , 14, e23-e33	3.1	3
297	Multimodal therapy in the treatment of metastatic prostate cancer: A case report. <i>Urology Case Reports</i> , 2018 , 21, 92-94	0.5	
296	Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy. <i>Journal of Clinical Gastroenterology and Hepatology</i> , 2018 , 2,	0	13
295	A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab 2018 , 6, 90		17
294	Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 500.e1-500.e9	2.8	23
293	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. <i>Nature Communications</i> , 2018 , 9, 3503	17.4	124
292	Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. <i>Oncogene</i> , 2018 , 37, 5858-5872	9.2	15
291	Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 287-298	5.4	4
290	The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. <i>Cancer</i> , 2017 , 123, 3532-3539	6.4	147
289	Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab 2017 , 5, 67		19
288	Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. <i>JCO Clinical Cancer Informatics</i> , 2017 , 1, 1-12	5.2	2
287	Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer. <i>JCO Clinical Cancer Informatics</i> , 2017 , 1, 1-10	5.2	7
286	Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. <i>Clinical Genitourinary Cancer</i> , 2017 ,	3.3	14
285	Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. <i>Medical Oncology</i> , 2017 , 34, 160	3.7	8
284	Hospital Centralization Impacts High-Risk Lung and Bladder Cancer Surgical Patients. <i>Cancer Investigation</i> , 2017 , 35, 652-661	2.1	8
283	Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 269-283	19.4	19

282	A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS3114-TPS3114	2.2	4
281	Correlation of consistent blood-based gene expression with change in CTLA4 in two large independent clinical studies of patients with advanced melanoma treated with tremelimumab.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6-6	2.2	
280	Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 36-36	2.2	
279	The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 319-327	1	16
278	Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2627-35	2.2	52
277	Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 825-32	2.2	116
276	Recognizing symptom burden in advanced prostate cancer: A global patient and caregiver survey.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10124-10124	2.2	2
275	Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4538-4538	2.2	4
274	Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression. <i>Oncotarget</i> , 2016 , 7, 68688-68707	3.3	4
273	Enzalutamide in Metastatic Castration Resistant Prostate Cancer 2016 , 157-169		
272	Frequency and clinical implications of pathologic complete response (pCR) at cystectomy for muscle-invasive bladder cancer (MIBC) with or without neoadjuvant chemotherapy (NAC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 383-383	2.2	
271	Blood-based predictive biomarkers for overall survival (OS) in patients (pts) receiving the immunotherapy sipuleucel-T (sip-T).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5026-5026	2.2	
270	Prognostic significance of PIK3CA mutation in patients with muscle-invasive urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16002-e16002	2.2	
269	Comparative effectiveness of treatment strategies for urothelial cancer of the bladder (UCB) with clinical lymph node involvement (cN+).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4530-4530	2.2	
268	Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma. <i>Bladder Cancer</i> , 2016 , 2, 341-349		4
267	Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion. <i>Anti-Cancer Drugs</i> , 2016 , 27, 235-8	2.4	2
266	A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer. <i>Prostate</i> , 2016 , 76, 1160-8	4.2	5
265	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma 2016 , 4, 92		25

264	Disease-specific classification using deconvoluted whole blood gene expression. <i>Scientific Reports</i> , 2016 , 6, 32976	4.9	15
263	Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer. <i>Oncologist</i> , 2016 , 21, 1414-e9	5.7	5
262	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. <i>European Urology</i> , 2016 , 70, 771-775	10.2	42
261	Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2015 , 33, 397-408	4.3	13
260	Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy. <i>Current Urology Reports</i> , 2015 , 16, 13	2.9	2
259	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015 , 26, 1589-604	10.3	220
258	A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 113-23	3.3	32
257	The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care. <i>Journal of Urology</i> , 2015 , 194, 36-41	2.5	22
256	Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. <i>Journal of Urology</i> , 2015 , 194, 91-7	2.5	50
255	Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). <i>BJU International</i> , 2015 , 116, 17-29	5.6	14
254	Geographic accessibility to clinical trials for advanced cancer in the United States. <i>JAMA Internal Medicine</i> , 2015 , 175, 293-5	11.5	21
253	Urological cancer: Is docetaxel the black widow of mCRPC drugs?. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 316-8	19.4	1
252	A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. <i>BMC Medicine</i> , 2015 , 13, 201	11.4	12
251	Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 1259-65	3.5	5
250	Renal Cell Carcinoma and Targeted Therapy 2015 , 287-295		1
249	Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. <i>Journal of Visualized Experiments</i> , 2015 , 53182	1.6	33
248	Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer. <i>Frontiers in Oncology</i> , 2015 , 5, 129	5.3	6
247	Clinical trial awareness: Changes over time and sociodemographic disparities. <i>Clinical Trials</i> , 2015 , 12, 215-23	2.2	38

246	Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. <i>Prostate</i> , 2015 , 75, 616-27	4.2	13
245	Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4586-4586	2.2	4
244	Comparative effectiveness of adjuvant chemotherapy (AC) versus observation in patients with \geq pT3 and/or pN+ bladder cancer (BCa).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 292-292	2.2	4
243	Influence of prostate cancer disease state and therapeutic selection on peripheral whole-blood RNA signature.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 166-166	2.2	0
242	Impact of obesity in patients with metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 346-346	2.2	
241	Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16029-e16029	2.2	
240	Influence of concurrent diabetes mellitus on clinical progression and response to androgen deprivation therapy in patients with advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16036-e16036	2.2	
239	Effectiveness of adjuvant chemotherapy (AC) versus observation in patients with \geq pT3 and/or pN+ bladder cancer (BCa).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4517-4517	2.2	
238	Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 48.e1-8	2.8	9
237	Adverse event reporting in cancer clinical trial publications. <i>Journal of Clinical Oncology</i> , 2014 , 32, 83-9	2.2	101
236	Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 465-71	3.5	14
235	Use of crowdsourcing for cancer clinical trial development. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	34
234	Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 90, 253-61	7	12
233	Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 30.e15-21	2.8	10
232	T2 muscle-invasive bladder cancer. <i>Seminars in Oncology</i> , 2014 , 41, e11-8	5.5	
231	Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. <i>International Journal of Oncology</i> , 2014 , 44, 5-16	4.4	30
230	Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 2202-2211	4.3	42
229	Adult cancer clinical trials that fail to complete: an epidemic?. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	66

228	Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. <i>Cancers</i> , 2014 , 6, 1298-327	6.6	99
227	Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2014 , 120, 833-9	6.4	21
226	Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. <i>Clinical Cancer Research</i> , 2014 , 20, 3310-8	12.9	22
225	Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma. <i>Oncologist</i> , 2014 , 19, 915-6	5.7	3
224	The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Urology</i> , 2014 , 6, 97-104	3.2	34
223	Metabolic complications with the use of mTOR inhibitors for cancer therapy. <i>Cancer Treatment Reviews</i> , 2014 , 40, 190-6	14.4	57
222	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. <i>Targeted Oncology</i> , 2014 , 9, 195-204	5	16
221	Premature termination of genitourinary cancer clinical trials.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 288-288		4
220	Distribution and geographic accessibility of prostate cancer clinical trials in the United States.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 59-59	2.2	1
219	Does race affect the quality of treatment for intermediate-risk and high-risk prostate cancer?. <i>Journal of Clinical Oncology</i> , 2014 , 32, e17678-e17678	2.2	
218	Use of crowdsourcing for cancer clinical trial development.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16019-e16019		
217	Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development. <i>Current Clinical Urology</i> , 2014 , 321-327		
216	Phase Ib/II trial of gemcitabine, cisplatin, plus lenalidomide as first-line therapy for patients with metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 321-321	2.2	
215	Meta-analysis of randomized trials to study the impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 28-28	2.2	
214	Biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 170-170	2.2	
213	Geographic and racial disparities in the utilization of low-volume cystectomy hospitals for bladder cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 302-302	2.2	
212	Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. <i>World Journal of Urology</i> , 2013 , 31, 1535-9	4	45
211	Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. <i>World Journal of Urology</i> , 2013 , 31, 1211-7	4	11

210	Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2013 , 16, 266-70	6.2	1
209	The impact of gender on outcomes in patients with metastatic urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 346-52	3.3	13
208	Tumour angiogenesis: an elusive target in castration-resistant prostate cancer. <i>Lancet Oncology, The</i> , 2013 , 14, 681-2	21.7	5
207	Metabolic and toxicological considerations of newly approved prostate cancer drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013 , 9, 835-46	5.5	4
206	Castration-resistant prostate cancer: AUA Guideline. <i>Journal of Urology</i> , 2013 , 190, 429-38	2.5	174
205	Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. <i>Cancer</i> , 2013 , 119, 3020-6	6.4	6
204	Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. <i>Cancer</i> , 2013 , 119, 3012-9	6.4	65
203	New paradigms in microtubule-mediated endocrine signaling in prostate cancer. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 555-66	6.1	16
202	TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression. <i>PLoS ONE</i> , 2013 , 8, e77366	3.7	68
201	Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 5015-5015	2.2	2
200	Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 256-256	2.2	5
199	Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 398-398	2.2	1
198	A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 59-59	2.2	5
197	Chemotherapy and Associated Symptoms 2013 , 835-858		
196	Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 251-251	2.2	
195	Evolving patterns of metastatic disease in castration-resistant prostate cancer (CRPC) reported in clinical trials from 1990 to 2011.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 195-195	2.2	
194	Cisplatin-based combination chemotherapy in elderly patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 269-269	2.2	
193	Association of Gleason 9-10 prostate cancer with worse outcomes compared to Gleason 8 disease.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e16032-e16032	2.2	

192	Blood mRNA signature to predict survival in patients with metastatic melanoma treated with tremelimumab.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 9080-9080	2.2	1
191	Prevalence and characteristics of prematurely terminated cancer clinical trials.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6613-6613	2.2	
190	Immune gene expression in primary melanomas to predict lower risk of recurrence and death.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3014-3014	2.2	
189	Cancer clinical trial accessibility in the United States: An analysis of travel distance.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 6540-6540	2.2	
188	Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. <i>Ca-A Cancer Journal for Clinicians</i> , 2012 , 62, 299-308	220.7	31
187	Bevacizumab treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2012 , 12, 1241-9	5.4	14
186	Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). <i>BJU International</i> , 2012 , 110, 1580-8	5.6	39
185	Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. <i>BJU International</i> , 2012 , 110, 1729-35	5.6	64
184	Trends in the use of cytoreductive nephrectomy in the United States. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 159-63	3.3	19
183	The emerging role of circulating tumor cell detection in genitourinary cancer. <i>Journal of Urology</i> , 2012 , 188, 21-6	2.5	37
182	659 RACIAL AND SOCIOECONOMIC DISPARITIES IN THE UTILIZATION OF NEPHRON-SPARING PROCEDURES FOR STAGE I KIDNEY CANCER IN THE UNITED STATES. <i>Journal of Urology</i> , 2012 , 187,	2.5	1
181	Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 848-55	2.8	9
180	A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. <i>Lancet Oncology, The</i> , 2012 , 13, 1105-13	21.7	93
179	Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. <i>Cancer Treatment Reviews</i> , 2012 , 38, 919-25	14.4	45
178	Emerging personalized approaches for the management of advanced urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012 , 12, 1537-43	3.5	6
177	Atypical metastases from prostate cancer: 10-year experience at a single institution. <i>American Journal of Roentgenology</i> , 2012 , 199, 367-72	5.4	88
176	Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. <i>Cancer</i> , 2012 , 118, 4777-84	6.4	40
175	Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. <i>Cancer</i> , 2012 , 118, 5947-54	6.4	31

174	Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 15-20	3.3	28
173	Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4416-26	2.2	152
172	Overcoming castration resistance in prostate cancer. <i>Current Opinion in Urology</i> , 2012 , 22, 167-74	2.8	11
171	Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1837-40	9.7	27
170	Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. <i>Annals of Oncology</i> , 2012 , 23, 1037-44	10.3	9
169	Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. <i>Annals of Oncology</i> , 2012 , 23, 406-10	10.3	144
168	Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4524-4524	2.2	4
167	Trends in the use of cytoreductive nephrectomy for metastatic renal cell carcinoma in the VEGFR tyrosine kinase inhibitor era.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4623-4623	2.2	1
166	Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4656-4656	2.2	1
165	Practice patterns in the use of adjuvant therapy for post-menopausal early-stage breast cancer in the pre- and post-Oncotype DX era.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e21032-e21032	2.2	
164	A validated whole-blood RNA transcript-based prognostic model that predicts survival in men with castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4516-4516	2.2	
163	Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e21016-e21016	2.2	
162	Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. <i>Urology</i> , 2011 , 78, 626-30	1.6	63
161	Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 756-63	2.8	9
160	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. <i>Lancet Oncology, The</i> , 2011 , 12, 211-4	21.7	186
159	Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. <i>Cancer Prevention Research</i> , 2011 , 4, 719-28	3.2	38
158	Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study. <i>Annals of Internal Medicine</i> , 2011 , 154, 727-36	8	68
157	Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. <i>BJU International</i> , 2011 , 107, 126-34	5.6	32

156	Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. <i>BJU International</i> , 2011 , 108, 1086-91	5.6	7
155	Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2011 , 9, 27-30	3.3	4
154	Secondary hormonal therapy in men with castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2011 , 9, 95-103	3.3	13
153	A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal [®] dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). <i>Investigational New Drugs</i> , 2011 , 29, 1465-74	4.3	71
152	PC3 is a cell line characteristic of prostatic small cell carcinoma. <i>Prostate</i> , 2011 , 71, 1668-79	4.2	276
151	Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. <i>Cancer</i> , 2011 , 117, 517-25	6.4	29
150	Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. <i>Cancer</i> , 2011 , 117, 1172-82	6.4	20
149	Endocrine therapy for prostate cancer: review of the latest clinical evidence. <i>Clinical Investigation</i> , 2011 , 1, 533-541		
148	Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. <i>Clinical Cancer Research</i> , 2011 , 17, 1546-52	12.9	15
147	Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. <i>Clinical Medicine Insights: Oncology</i> , 2011 , 5, 163-9	1.8	8
146	The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. <i>Cancer Prevention Research</i> , 2011 , 4, 2044-50 ²	5.2	20
145	Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2432-8	2.2	349
144	SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2565-73	2.2	134
143	Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy. <i>Asian Journal of Andrology</i> , 2011 , 13, 181-2	2.8	
142	Cabazitaxel. <i>Nature Reviews Drug Discovery</i> , 2010 , 9, 677-8	64.1	124
141	Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. <i>BJU International</i> , 2010 , 105, 1247-54	5.6	56
140	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. <i>BJU International</i> , 2010 , 106, 772-8	5.6	73
139	Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. <i>Annals of Oncology</i> , 2010 , 21, 312-318	10.3	32

138	Genome-wide association study of prostate cancer mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2869-76	4	42
137	Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1871-8	4	16
136	Castration-resistant prostate cancer: new science and therapeutic prospects. <i>Therapeutic Advances in Medical Oncology</i> , 2010 , 2, 189-207	5.4	19
135	Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. <i>Clinical Cancer Research</i> , 2010 , 16, 5244-51	12.9	32
134	Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. <i>PLoS Genetics</i> , 2010 , 6, e1001204	6	70
133	Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article. <i>Journal of Neurosurgery: Spine</i> , 2010 , 13, 789-94	2.8	30
132	Neoadjuvant and adjuvant therapies in prostate cancer. <i>Urologic Clinics of North America</i> , 2010 , 37, 97-104, Table of Contents	2.9	8
131	Cytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2010 , 7, 17-22		1
130	Photoluminescent polymer nanoparticles for label-free cellular imaging. <i>Chemical Communications</i> , 2010 , 46, 5229-31	5.8	36
129	Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?. <i>Urology</i> , 2010 , 75, 642-7	1.6	23
128	Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. <i>BJU International</i> , 2010 , 105, 1392-6	5.6	20
127	Cancer therapy from bench to bedside. <i>Mount Sinai Journal of Medicine</i> , 2010 , 77, 571-2		
126	Sixty years of CA: a cancer journal for clinicians. <i>Ca-A Cancer Journal for Clinicians</i> , 2010 , 60, 345-50	220.7	61
125	Platinum Agents in Prostate Cancer 2010 , 153-161		
124	Cancer of the Genitourinary Tract 2010 , 233-277		
123	Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3577-83	2.2	61
122	Phase II study of sunitinib in men with advanced prostate cancer. <i>Annals of Oncology</i> , 2009 , 20, 913-20	10.3	122
121	Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 7099-105	12.9	59

120	Functional enhancers at the gene-poor 8q24 cancer-linked locus. <i>PLoS Genetics</i> , 2009 , 5, e1000597	6	189
119	Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. <i>Clinical Cancer Research</i> , 2009 , 15, 3223-30	12.9	44
118	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5794-9	2.2	1390
117	Evaluation of the 8q24 prostate cancer risk locus and MYC expression. <i>Cancer Research</i> , 2009 , 69, 5568-74	6.1	102
116	The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. <i>Clinical Genitourinary Cancer</i> , 2009 , 7, E71-6	3.3	21
115	Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. <i>Clinical Genitourinary Cancer</i> , 2009 , 7, E90-2	3.3	14
114	Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. <i>Cancer</i> , 2009 , 115, 981-7	6.4	87
113	Absence of relationship between steroid hormone levels and prostate cancer tumor grade. <i>Urology</i> , 2009 , 73, 356-61; discussion 361-2	1.6	28
112	CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. <i>Human Pathology</i> , 2009 , 40, 252-8	3.7	61
111	Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. <i>Clinical Genitourinary Cancer</i> , 2009 , 7, 51-7	3.3	20
110	Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. <i>Current Medical Research and Opinion</i> , 2009 , 25, 2081-90	2.5	16
109	Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report. <i>Cases Journal</i> , 2009 , 2, 7273		1
108	Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. <i>IDrugs: the Investigational Drugs Journal</i> , 2009 , 12, 165-8		1
107	Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. <i>British Journal of Cancer</i> , 2008 , 99, 1426-32	8.7	12
106	Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. <i>BJU International</i> , 2008 , 101, 308-12	5.6	37
105	Use of androgen deprivation therapy for metastatic prostate cancer in older men. <i>BJU International</i> , 2008 , 101, 1077-83	5.6	19
104	A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. <i>BJU International</i> , 2008 , 101, 1084-9	5.6	54
103	Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 506-7		22

102	What is the current status of second-line chemotherapy for castration-resistant prostate cancer?. <i>Nature Reviews Urology</i> , 2008 , 5, 650-1		1
101	Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 842-7	2.2	86
100	Relationship between serum adiponectin and prostate cancer grade. <i>Prostate</i> , 2008 , 68, 1592-8	4.2	41
99	A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. <i>Cancer</i> , 2008 , 112, 521-6	6.4	89
98	Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. <i>Cancer</i> , 2008 , 112, 1247-53	6.4	91
97	Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. <i>Journal of Urology</i> , 2007 , 177, 2146-50	2.5	22
96	Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?. <i>Cancer</i> , 2007 , 109, 477-86	6.4	54
95	The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. <i>Cancer</i> , 2007 , 109, 1090-6	6.4	31
94	Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. <i>Cancer</i> , 2007 , 110, 2709-15	6.4	7
93	The medical management of prostate cancer: a multidisciplinary team approach. <i>BJU International</i> , 2007 , 99, 22-7	5.6	26
92	Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. <i>Clinical Cancer Research</i> , 2007 , 13, 5816-24	12.9	80
91	Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. <i>Journal of Immunotherapy</i> , 2007 , 30, 749-61	5	102
90	Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2007 , 13, 125-9	2.2	12
89	Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. <i>Urology</i> , 2007 , 70, 527-31	1.6	17
88	Development of an integrated prostate cancer research information system. <i>Clinical Genitourinary Cancer</i> , 2006 , 5, 61-6	3.3	50
87	A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. <i>Cancer</i> , 2006 , 106, 58-62	6.4	28
86	Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. <i>Cancer</i> , 2006 , 107, 530-5	6.4	40
85	Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. <i>Cancer</i> , 2006 , 107, 975-81	6.4	38

84	Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2723-8	2.2	114
83	Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 152-8	12.9	23
82	Carboplatin for stage I seminoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2971-2; author reply e32-3	2.2	4
81	Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2958-9	2.2	4
80	Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. <i>Journal of Urology</i> , 2006 , 176, 1927-37	2.5	33
79	Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?. <i>Urology</i> , 2006 , 67, 1084.e15-7	1.6	13
78	Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. <i>Urology</i> , 2006 , 67, 1235-40	1.6	46
77	Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006 , 24, 503-8	2.8	12
76	Recent progress in hormonal therapy for advanced prostate cancer. <i>Current Opinion in Urology</i> , 2006 , 16, 173-8	2.8	24
75	Chemotherapy for high-risk localized prostate cancer. <i>BJU International</i> , 2006 , 97, 679-83	5.6	4
74	CO4 A COMPARISON OF LOGISTIC REGRESSION AND COX PROPORTIONAL HAZARDS MODELS FOR IDENTIFICATION OF RISK FACTORS FOR RENAL IMPAIRMENT IN HORMONE REFRACTORY PROSTATE CANCER (HRPC) PATIENTS WITH BONE METASTASES (BM) TREATED WITH ZOLEDRONIC ACID (ZA). <i>Value in Health</i> , 2005 , 8, A16-A17	3.3	2
73	Docetaxel in Hormone-Refractory Metastatic Prostate Cancer. <i>Drugs</i> , 2005 , 65, 2295-2297	12.1	1
72	Docetaxel in Hormone-Refractory Metastatic Prostate Cancer. <i>Drugs</i> , 2005 , 65, 2295-2297	12.1	
71	Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. <i>Clinical Prostate Cancer</i> , 2005 , 4, 61-4		10
70	Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. <i>BJU International</i> , 2005 , 96, 783-6	5.6	21
69	Metastatic Adenocarcinoma of the Prostate 2005 , 505-513		
68	High-risk localized prostate cancer: integrating chemotherapy. <i>Oncologist</i> , 2005 , 10 Suppl 2, 18-22	5.7	11
67	Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1439-46	2.2	168

66	Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 5233-40	12.9	151
65	A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 284-9	12.9	22
64	A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 924-8	12.9	58
63	Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3705-12	2.2	99
62	Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. <i>Annals of Oncology</i> , 2004 , 15, 974-8	10.3	25
61	Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer. <i>Current Treatment Options in Oncology</i> , 2004 , 5, 349-55	5.4	
60	Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. <i>Cancer</i> , 2004 , 101, 1569-74	6.4	116
59	Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. <i>Clinical Prostate Cancer</i> , 2004 , 3, 49-53		69
58	An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer. <i>Journal of Urology</i> , 2004 , 172, S34-7; discussion S37	2.5	5
57	Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. <i>Urology</i> , 2004 , 63, 327-32	1.6	25
56	A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004 , 22, 393-7	2.8	54
55	. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, 312-316	2.7	2
54	Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003 , 26, 312-6	2.7	2
53	Neoadjuvant therapy for high-risk localized prostate cancer. <i>Current Oncology Reports</i> , 2003 , 5, 250-7	6.3	1
52	Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma. <i>Cancer</i> , 2003 , 97, 2171-9	6.4	6
51	A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. <i>Cancer</i> , 2003 , 98, 2592-8	6.4	81
50	Male patients with diagnoses of both breast cancer and prostate cancer. <i>Breast Journal</i> , 2003 , 9, 208-12	1.2	15
49	Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. <i>Journal of Urology</i> , 2003 , 170, S3-5	2.5	4

48	Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results. <i>Journal of Urology</i> , 2003 , 170, 1305	2.5	1
47	Prostate-specific antigen doubling time predicts disease progression and survival. <i>Clinical Prostate Cancer</i> , 2003 , 1, 208-11		1
46	Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. <i>Urology</i> , 2003 , 62, 99-104	1.6	18
45	Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. <i>Urology</i> , 2003 , 62, 324-7	1.6	85
44	Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2003 , 21, 229-34	2.8	6
43	The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer. <i>Journal of Urology</i> , 2003 , 170, S28-32; discussion S33-4	2.5	15
42	Transitional cell carcinoma of the upper uroepithelial tract. <i>Clinical Advances in Hematology and Oncology</i> , 2003 , 1, 102-4; discussion 105	0.6	
41	Complementary and alternative therapies in prostate cancer. <i>Seminars in Oncology</i> , 2002 , 29, 575-84	5.5	17
40	Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases. <i>Cancer</i> , 2002 , 94, 686-9	6.4	12
39	Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. <i>Cancer</i> , 2002 , 95, 275-80	6.4	18
38	Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. <i>Cancer</i> , 2002 , 95, 1864-8	6.4	43
37	A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. <i>Cancer Investigation</i> , 2002 , 20, 186-91	2.1	4
36	The evolving role of estrogen therapy in prostate cancer. <i>Clinical Prostate Cancer</i> , 2002 , 1, 81-9		65
35	Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. <i>Urology</i> , 2002 , 60, 1-6	1.6	24
34	Secondary hormonal therapies in the treatment of prostate cancer. <i>Urology</i> , 2002 , 60, 87-92; discussion 93	1.6	54
33	PROGRESSIVE SCLEROSIS OF ISOLATED FOOT METASTASIS OF PROSTATE CANCER. <i>Journal of Urology</i> , 2002 , 167, 1392-1392	2.5	5
32	PC-SPES and prostate cancer. <i>Urologic Clinics of North America</i> , 2002 , 29, 59-66, viii	2.9	6
31	Progressive sclerosis of isolated foot metastasis of prostate cancer. <i>Journal of Urology</i> , 2002 , 167, 1392	2.5	3

30	Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. <i>Seminars in Oncology</i> , 2001 , 28, 40-4	5.5	58
29	Anemia Related to Hormonal Ablation Therapy for Prostate Cancer. <i>Prostate Journal</i> , 2001 , 3, 14-17		3
28	Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow-up. <i>Prostate Journal</i> , 2001 , 3, 42-43		4
27	Overall Survival after Prostate-Specific-Antigen-Detected Recurrence Following Conformal Radiation Therapy.. <i>Prostate Journal</i> , 2001 , 3, 43-44		
26	Prospective Trial of the Herbal Supplement PC-SPEC in Patients with Progressive Prostate Cancer.. <i>Prostate Journal</i> , 2001 , 3, 44-45		
25	Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. <i>Urology</i> , 2001 , 57, 122-6	1.6	54
24	Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. <i>Journal of Clinical Oncology</i> , 2001 , 19, 44-53	2.2	158
23	Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report. <i>Seminars in Oncology</i> , 2001 , 28, 40-44	5.5	2
22	Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. <i>Cancer</i> , 2000 , 88, 3015-21	6.4	47
21	Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study. <i>Cancer</i> , 2000 , 89, 1824-8	6.4	28
20	Article Reviews. <i>Prostate Journal</i> , 2000 , 2, 102-105		
19	Article Reviews. <i>Prostate Journal</i> , 2000 , 2, 163-167		
18	Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1921-7	2.2	192
17	Nonmalignant diagnoses in patients. Case 3. Right atrial thrombus associated with a central venous catheter in a patient with metastatic adrenocortical carcinoma. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2638-9	2.2	4
16	Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 10990-5	11.5	362
15	Smoking and alcohol use may be risk factors for poorer outcome in patients with clear cell renal carcinoma. <i>Urology</i> , 2000 , 55, 31-5	1.6	22
14	Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3461-7	2.2	839
13	Treatment of locally advanced prostate cancer: is chemotherapy the next step?. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3664-75	2.2	33

12	Antiandrogens in prostate cancer. <i>Investigational New Drugs</i> , 1999 , 17, 271-84	4.3	44
11	Article Reviews. <i>Prostate Journal</i> , 1999 , 1, 103-108		
10	Phase II Trial of the Antiestrogen Toremifene for Androgen-Independent Prostate Cancer. <i>Prostate Journal</i> , 1999 , 1, 185-189		1
9	Article Reviews. <i>Prostate Journal</i> , 1999 , 1, 203-207		
8	A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. <i>Cancer</i> , 1999 , 86, 1329-34	6.4	5
7	Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. <i>Urology</i> , 1999 , 54, 1064-7	1.6	88
6	PACLITAXEL(T), ESTRAMUSTINE(E) AND CARBOPLATIN(C) IN PATIENTS (Pts) WITH ADVANCED PROSTATE CANCER(PC). <i>Journal of Urology</i> , 1999 , 177	2.5	3
5	MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS. <i>Journal of Urology</i> , 1998 , 160, 1220-1229	2.5	205
4	MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER. <i>Journal of Urology</i> , 1998 , 1220-1229	2.5	12
3	Multicenter Trial of Single-Dose Modified Bovine Surfactant Extract (Survanta) for Prevention of Respiratory Distress Syndrome. <i>Pediatrics</i> , 1990 , 85, 1092-1102	7.4	29
2	Correlation of the interpretation of fetal heart rate records with cord plasma erythropoietin levels. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1985 , 92, 326-32	3.7	19
1	Renal metabolism in fetal and newborn sheep. <i>Pediatric Research</i> , 1985 , 19, 641-4	3.2	14